• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vaxcyte Inc. (Amendment)

    2/13/24 5:16:09 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    SC 13G/A 1 tv02192-vaxcyteinc.htm SCHEDULE 13G/A vaxcyteinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Vaxcyte Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  92243G108

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  92243G108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    167,868

    7.  SOLE DISPOSITIVE POWER

    8,196,241

    8.  SHARED DISPOSITIVE POWER

    256,130

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,452,371

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.88%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Vaxcyte Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    825 Industrial Road, Suite 300
    San Carlos, CA 94070

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    92243G108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $PCVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    12/29/2021$50.00Buy
    Jefferies
    More analyst ratings

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brandicourt Olivier

      4 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:28:47 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Brandicourt Olivier claimed no ownership of stock in the company (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:27:02 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      4/25/25 4:13:50 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints John Furey to Board of Directors

      SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

      7/2/24 8:30:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Whitney Jones as Chief People Officer

      -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

      1/16/24 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Vaxcyte

      Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

      4/22/25 7:35:12 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vaxcyte with a new price target

      Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

      12/20/24 7:47:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Vaxcyte with a new price target

      Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00

      12/7/23 7:01:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 5:46:11 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 2:53:06 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/12/24 10:34:18 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    SEC Filings

    See more

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

      SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      5/15/25 4:51:54 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Vaxcyte Inc.

      10-Q - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:23:38 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:03:56 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig

      5/7/25 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Financials

    Live finance-specific insights

    See more
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

      SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

      3/30/25 5:00:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

      2/12/25 4:05:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care